Patents by Inventor Leslie S. Johnson

Leslie S. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210275685
    Abstract: The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain- containing Protein 9” (“ADAM9”) conjugated to at least one maytansinoid compound. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 9, 2021
    Inventors: Stuart William Hicks, Nicholas C. Yoder, Bhaswati Barat, Ezio Bonvini, Gundo Diedrich, Leslie S. Johnson, Deryk Loo, Juniper A. Scribner
  • Patent number: 11111299
    Abstract: The present invention relates to CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: September 7, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ling Huang, Leslie S. Johnson
  • Patent number: 11098119
    Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”).
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 24, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
  • Patent number: 11098125
    Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: August 24, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Robyn Gerena
  • Publication number: 20210246194
    Abstract: The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 12, 2021
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Chia-Ying Kao Lam, Gundo Diedrich, Jeffrey Lee Nordstrom, Liqin Liu, Leslie S. Johnson, Scott Koenig, Barton F. Haynes, Guido Ferrari
  • Patent number: 11072653
    Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 27, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210206851
    Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 8, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210171630
    Abstract: The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 10, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Gundo Diedrich, Liqin Liu, Hua Watson Li, Leslie S. Johnson
  • Publication number: 20210171641
    Abstract: The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Application
    Filed: December 17, 2020
    Publication date: June 10, 2021
    Inventors: Deryk T. LOO, Ling Huang, Leslie S. Johnson, Thomas Son, Juniper A. Scribner, Ezio Bonvini
  • Patent number: 11028183
    Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 8, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
  • Publication number: 20210155694
    Abstract: The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRHI Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL I Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain.
    Type: Application
    Filed: February 13, 2019
    Publication date: May 27, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Ling Huang, Chia-Ying Kao Lam, Gurunadh Reddy Chichili, Ralph Froman Alderson, Paul A. Moore, Leslie S. Johnson
  • Publication number: 20210130470
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Inventors: Leslie S. JOHNSON, Gurunadh Reddy CHICHILI, Kalpana SHAH, Ross LA MOTTE-MOHS, Paul A. Moore, Ezio Bonvini, Scott KOENIG
  • Publication number: 20210107998
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 15, 2021
    Inventors: Sanjaya SINGH, Qi PAN, Rachel Rebecca BARRETT, Leslie S. JOHNSON, Pankaj GUPTA, Sarah LOW, Haixia WU
  • Publication number: 20210095021
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Application
    Filed: June 22, 2020
    Publication date: April 1, 2021
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Patent number: 10961311
    Abstract: The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: March 30, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Deryk T. Loo, Ling Huang, Leslie S. Johnson, Thomas Son, Juniper A. Scribner, Ezio Bonvini
  • Patent number: 10954301
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: March 23, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210054065
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 26, 2020
    Publication date: February 25, 2021
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Publication number: 20210047426
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Application
    Filed: August 24, 2020
    Publication date: February 18, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Patent number: 10858430
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 8, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Publication number: 20200377612
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: December 3, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen